Research summary

UAE obesity estimates differ across sources because surveys use different populations, age groups and measurement methods. The article brings together national survey results and international estimates.MOHAP IDF

All figures should be read with the source, year and population stated in the article.

Summary revised November 1, 2026. This editorial update does not constitute a new literature review.

UAE Obesity Statistics — Key Data
Metric Value Source / Year
Adults living with obesity in the UAE (national survey, ages 18+) 22.4% MoHAP National Health and Nutrition Survey 2024–2025
Adults living with overweight or obesity in Dubai (DAHC records) 63.4% Abdelgadir et al. 2025
Adults living with obesity in Dubai (DAHC records) 28.0% Abdelgadir et al. 2025
Adults living with obesity in Dubai (household survey) 17.8% Dubai Household Health Survey 2019 (Mamdouh et al. 2023)
UAE nationals living with overweight or obesity in the Dubai dataset 68.3% Abdelgadir et al. 2025
Adult obesity in the UAE, age-standardized 31.6% WHO data portal, 2024 estimate (May 2026 release)
Female adult obesity in the UAE, age-standardized 38.4% WHO data portal, 2024 estimate (May 2026 release)
Male adult obesity in the UAE, age-standardized 27.8% WHO data portal, 2024 estimate (May 2026 release)
Adults with diabetes in the UAE 1.274 million IDF Diabetes Atlas, 2024 estimate
Diabetes prevalence in the UAE, age-standardized 20.7% IDF Diabetes Atlas, 2024 estimate
Share of diabetes cases undiagnosed 64.0% IDF Diabetes Atlas, 2024 estimate
Economic impact of obesity by 2035 Almost 5% of GDP World Obesity Federation, 2024 briefing
UAE GLP-1 market revenue USD 257.2M in 2025 Grand View Research
UAE GLP-1 market forecast USD 875.9M by 2033 Grand View Research
UAE GLP-1 market growth rate 15.3% CAGR Grand View Research, 2026-2033
How To Read The Numbers
National Baseline
Best for cross-country comparison
  • WHO age-standardized adult obesity estimate: 31.6% in 2024 (uncertainty interval 27.1–36.3%)
  • Female estimate: 38.4%
  • Male estimate: 27.8%
  • Useful when comparing the UAE with peer countries
Dubai Service-Population Snapshot
Best for operational burden in Dubai
  • 440,590 adults seen across Dubai Academic Health Corporation sites
  • 63.4% living with overweight or obesity
  • 28.0% living with obesity
  • UAE nationals reached 68.3% overweight or obesity
Metabolic Spillover
Best for understanding category demand
  • 1.274 million adults with diabetes in 2024
  • 20.7% age-standardized diabetes prevalence
  • 64.0% of diabetes cases estimated undiagnosed
  • World Obesity projects obesity costs could approach 5% of GDP by 2035

What Is the UAE Obesity Rate, and Which Figure Should You Use?

MoHAP’s National Health and Nutrition Survey 2024–2025 found 22.4% of adults aged 18 and over living with obesity. It covered 20,000 households across the UAE and 2,000 people living in workers’ accommodation, and it is the most recent national survey figure.

Even so, there is no single UAE obesity number; there are different numbers for different jobs. WHO’s age-standardized national estimate is the right reference if the goal is cross-country comparison. The Dubai Academic Health Corporation paper is more useful if the goal is to understand the burden showing up in a large real-world urban health-system sample. The two should not be treated as contradictory. They measure different populations and different summary frames.

The Dubai study is especially important because it is the largest obesity prevalence dataset yet published from the region, covering 440,590 adults attending public-sector sites between 2018 and 2023. It found that 63.4% were living with overweight or obesity and 28.0% with obesity. UAE nationals had a heavier burden than other population groups in the dataset, reaching 68.3% living with overweight or obesity. For searchers asking why UAE obesity figures look different across websites, this is usually the answer: some pages cite a national obesity-only estimate, while others cite a Dubai overweight-plus-obesity sample.

A cross-sectional study of 688 adolescents aged 14–18 in the UAE, published in Cureus on October 11, 2026, measured overweight or obesity in 39.8% of participants, including 12.5% with obesity. The authors note that the sample is not nationally representative.

Here, the job is not to tell readers what a prescription product costs. It is to explain why the UAE has become such an important metabolic-disease market in the first place, which starts with reading the burden data correctly.

Evidence and context

The UAE obesity rate is 22.4% of adults aged 18 and over in the MoHAP National Health & Nutrition Survey 2024–2025 (published January 6, 2026), with childhood obesity at 16.1% (ages 6–17) and 2.2% (ages 0–5). The WHO’s age-standardized national estimate puts adult obesity at 31.6% in 2024, and the largest Dubai population study found 63.4% of adults living with overweight or obesity and 28.0% with obesity. The metabolic spillover is equally important: IDF estimates 1.274 million adults in the UAE had diabetes in 2024, with an age-standardized prevalence of 20.7% and 64.0% undiagnosed. That burden helps explain why the UAE GLP-1 category is expanding quickly, but the bigger signal is structural: MoHAP frames obesity as a strategic priority, and market-intelligence firms expect the UAE GLP-1 market to keep compounding through 2033.

How Large Is the Linked Diabetes and Obesity Burden?

The obesity conversation becomes much more consequential once it is paired with the UAE diabetes profile. The IDF Diabetes Atlas 11th edition estimates that 1.274 million adults in the UAE were living with diabetes in 2024, and that the age-standardized prevalence was 20.7%. That is why the UAE repeatedly appears in global metabolic-disease discussions even when country-level obesity estimates vary by method.

One of the most important details in the IDF profile is not prevalence alone but detection. The Atlas estimates that 64.0% of diabetes cases in the UAE are undiagnosed. That matters for market interpretation: a large metabolic burden does not automatically mean neat, fully identified treatment pathways. It means health systems, screening programs, primary care, and pharmacy demand can all move at different speeds.

A cross-sectional analysis of 5,050 adults aged 18–40 in the UAE Healthy Future Study, published in Frontiers in Public Health in September 2026, found metabolic syndrome in 22.4% of participants (26.1% of men and 16.7% of women). Abdominal obesity was present in 39%.

For GLP-1 research, that combination of high excess-weight burden, high diabetes prevalence, and large undiagnosed share is the real story. It creates a market where demand is not being driven by one variable such as aesthetics or trend usage alone. The category sits on top of a broader metabolic screening and chronic-disease problem.

What Is the Official United Arab Emirates Policy Response?

The official stance has become clearer in the last year. In March 2025, MoHAP described obesity as a strategic priority for the UAE health system. Its burden extends well beyond diabetes to cardiovascular disease and other chronic conditions: higher-than-optimal body weight is linked to an estimated 3.7 million deaths a year worldwide and is a major risk factor for several cancers. In the same update, the ministry pointed to collaboration with WHO, school-health and childhood-obesity initiatives, training on obesity indicators, and work on a national scientific guide for obesity management and weight control, in line with broader clinical practice recommendations.

MoHAP also said the then-upcoming National Health and Nutrition Survey would measure obesity rates among adults and children across the country, including body mass index, waist circumference, and clearer obesity-diagnosis thresholds. That survey (2024–2025) was published on January 6, 2026 and reports 22.4% of adults living with obesity. That matters because it signals a move from broad awareness messaging toward more standardized national measurement. For researchers and analysts, that is one of the strongest clues that obesity in the UAE is now being treated as an infrastructure question, not just a lifestyle topic — a direction reinforced by the role of the Dubai Health Authority and routine sampling in public health facilities as the system builds more consistent national data.

On October 6, 2026, MoHAP said it had started implementing a resolution that caps sodium, sugar and fat in selected packaged foods, including bread, sweetened milk drinks, flavoured yoghurt and laban, salty snacks and processed cheese. The limits apply in two phases, with final limits due by December 31, 2030, and the ministry linked the measure to reducing obesity and other noncommunicable diseases.

On October 7, 2026, the World Health Organization issued its first global guidelines on obesity in children and adolescents. WHO does not recommend medicines, surgery or weight-loss devices for children aged 0–9. For adolescents aged 10–19, it says approved medicines may be considered only when a supervised lifestyle programme has not worked.

World Obesity Federation arrives at the same issue from a different angle. Its 2024 UAE briefing warns that the economic impact of obesity is on track to approach 5% of GDP by 2035. That estimated total folds in indirect costs such as lost productivity alongside direct healthcare spending, and it reflects rising pressure for prevention and treatment pathways, including earlier lifestyle intervention. The figure is not a prevalence number, but it is a useful reminder that the UAE obesity story is already an economic and system-capacity story, not only an individual-risk story.

UAE Weight Loss Market: What the GLP-1 Data Suggests
Market Intelligence Snapshot
Clearly labeled report data, not official utilization counts
  • Grand View Research estimates UAE GLP-1 revenue at USD 257.2M in 2025
  • The same source forecasts USD 875.9M by 2033
  • Forecast CAGR: 15.3% from 2026 to 2033
  • Semaglutide is the largest segment in the report; tirzepatide is the fastest-growing
Why Growth Looks Plausible
Burden + screening gap + policy focus
  • Large obesity burden in both WHO and Dubai datasets
  • High diabetes prevalence with a large undiagnosed share
  • MoHAP now frames obesity as a strategic priority
  • Economic-cost framing raises pressure for earlier intervention pathways

How Should Readers Interpret the UAE GLP-1 and Lifestyle Intervention Landscape?

The right interpretation is that UAE GLP-1 demand is being built by epidemiology first and product competition second. Obesity and diabetes prevalence create the underlying demand pool; policy attention, screening efforts, and clinician adoption determine how fast that demand becomes visible in prescribing and pharmacy channels. This is why the UAE matters in the broader incretin conversation even when brand-level pricing or availability changes month to month. Alongside the new National Health and Nutrition Survey 2024–2025 (adult obesity 22.4%), the earlier UAE National Health Survey 2017–2018 remains a useful benchmark, reporting adult obesity at 27.8%. In practice, an obesity diagnosis is often standardized with more than body mass index alone, with waist circumference also used to gauge cardiometabolic risk.

For brand comparisons, see Ozempic vs Mounjaro vs Wegovy; for approval status, see the obesity drug approval tracker. If you need the why now behind the UAE metabolic market, this is the better starting point. It is also why screening and treatment capacity belong in the picture: obesity care spans lifestyle intervention and structured medical management through to bariatric surgery in severe cases, and how much of that pathway a health system can deliver shapes how underlying burden converts into measured demand.

2026 Landscape Updates

UAE Approval of Foundayo — April 3, 2026 (Second Country Worldwide)

The UAE medicines regulator announced its approval of Foundayo (orforglipron) on April 3, 2026, making the UAE the second country in the world to register this oral small-molecule (non-peptide) GLP-1 receptor agonist for chronic weight management. First supplies became available in May 2026. On April 24, 2026 the Abu Dhabi Department of Health added Foundayo to its Personalised Weight Management Programme with the Abu Dhabi Public Health Centre, covering eligible adults, with Imperial College London Diabetes & Endocrine Centre handling the initial rollout. The FDA had approved Foundayo on April 1, 2026. On October 15, 2026, the European Medicines Agency’s human medicines committee (CHMP) recommended EU marketing authorisation for Foundayo for weight management and type 2 diabetes in adults. EMA announced the opinion on October 16, and a European Commission decision is pending. Unlike Rybelsus or other oral peptide formulations, it has no food or water restrictions. For mechanism, dosing, and trial data, see the Foundayo orforglipron profile. Sources: gulfnews.com; doh.gov.ae; ema.europa.eu.

Novo Nordisk: UAE Global Pharmaceutical Distribution Hub (May 22, 2026)

Novo Nordisk and UAE health authorities announced on May 22, 2026 that the UAE would serve as one of three global pharmaceutical distribution hubs worldwide, supporting approximately 70 countries and 2.6 million patients. This is a supply-chain and trust signal: distribution infrastructure for incretin medicines is being built in partnership with the UAE federal regulator. Sources: gulfnews.com; healthcaremea.com; khaleejtimes.com.

Retatrutide TRIUMPH-1 Readout — May 21, 2026

Retatrutide’s pivotal TRIUMPH-1 obesity readout was reported on May 21, 2026 and is relevant input for landscape forecasting in this region. Retatrutide remains investigational and is not an approved UAE medicine; nothing here suggests otherwise. The reason it earns a place in a UAE obesity-landscape page is forward-looking: triple-agonist Phase 3 data anchors where the obesity pharmacology ceiling is heading, and that ceiling moves how analysts size the regional category over the next several years. UAE regulatory pathways for retatrutide are not yet announced and we do not speculate on them. See the Dubai research guide for full research-use context.

Retatrutide TRIUMPH-2 and TRIUMPH-3 — July 23, 2026; FDA Filing Planned Q1 2027

Lilly reported two more positive Phase 3 toplines on July 23, 2026. In TRIUMPH-2 (adults with obesity and type 2 diabetes, 80 weeks), mean weight loss (efficacy estimand) was 12.7%, 19.1% and 20.8% at 4, 9 and 12 mg versus 4.0% on placebo, with A1C reductions of up to 1.6 points. In TRIUMPH-3 (severe obesity with established cardiovascular disease, 80 weeks), weight loss (efficacy estimand) was 21.6% and 22.6% at 9 and 12 mg versus 3.2% on placebo. TRIUMPH-1 was published in the New England Journal of Medicine and TRIUMPH-2 in The Lancet on September 29, 2026; the Lancet paper reports 11.9%, 16.8% and 18.8% versus 5.1% on placebo by the treatment-regimen estimand. Lilly plans to submit retatrutide for US approval in Q1 2027. Retatrutide is not approved anywhere, including the UAE, and Eli Lilly says it is legally available only to participants in its clinical trials. Approval timing across the category is tracked in the retatrutide approval tracker.

Wegovy Pill — UAE Approval (June 1, 2026) and Launch

The UAE medicines regulator approved oral Wegovy (semaglutide) on June 1, 2026 for weight management and cardiovascular risk reduction, making the UAE the second country to authorise it. Novo Nordisk launched the pill in the UAE on June 3, 2026, its first market outside the US. When the European Commission approved the Wegovy pill on July 15, 2026, Novo said it was already available in the United States, the UK and the UAE; Germany, its first EU launch market, followed on September 1, 2026. Sources: finance.yahoo.com; reuters.com; reuters.com.

Incretin Market Scale — Lilly Q2 & Novo Q1 2026

Global incretin demand helps frame UAE projections. Lilly Q2 2026 (August 5, 2026): Mounjaro WW revenue $9.9B (+91% YoY); Zepbound $4.9B (+44%); total Lilly $23.0B (+48%); Foundayo $98M in its first reported quarter. Novo Nordisk Q1 2026 (May 6, 2026): total DKK 96.8B (+32% CER); obesity care +22% CER; Wegovy pill first launch quarter DKK 2.26B. Cited as global market-size context. Sources: prnewswire.com; novonordisk.com.

UAE 2031 Obesity Macro Report — Whiteshield, May 2026

A May 2026 report, Beneath the Surface: The Hidden Socioeconomic Impacts of Weight Loss, produced by Whiteshield and commissioned by Eli Lilly with the UAE Ministry of Economy and Tourism, modelled accelerated intervention outcomes: 1.2M+ adults could exit obesity by 2031, delivering a ~15-percentage-point prevalence decline, +$51B in GDP, and $1.5B in healthcare savings. This is a forward-looking economic model, prepared in collaboration with a UAE ministry, signaling that obesity has moved firmly into the national economic-development agenda. Sources: aletihad.ae; healthcaremea.com; emirates247.com.

Where Does Retatrutide Fit in This Landscape?

Retatrutide belongs in the research and pipeline layer, not the approved-prescription layer. It is a next-generation triple-agonist candidate often discussed alongside semaglutide, tirzepatide, and CagriSema when analysts map where obesity pharmacology may be heading. On this site, it is covered strictly in research-use terms and should not be presented as an approved UAE treatment product. For research-use context, Remy Research lists 18 retatrutide formats in its UAE catalogue; six (the Remedium 30mg pen and the ProPeptide pens and vials) link a published Janoshik batch report, three of them through a supplier-mapped batch, and the ZPHC and Genovare lines show their COA status on each product page.

If you want a deeper research-only breakdown, use our Dubai research guide. If you want a mechanism and pipeline comparison, use our retatrutide vs tirzepatide vs CagriSema analysis. For approval timing across the wider category, use the obesity drug approval tracker.

The UAE adult obesity rate is 22.4% in MoHAP’s National Health and Nutrition Survey 2024–2025, published in January 2026. WHO’s modelled estimate puts age-standardized adult obesity at 31.6% in 2024. The largest Dubai population study found 63.4% of adults were living with overweight or obesity and 28.0% with obesity. They measure different populations, so they are not interchangeable.
MoHAP’s January 2026 release of the national survey gives a UAE-wide figure only. Two peer-reviewed studies give Dubai figures. The Dubai Household Health Survey 2019, a weighted sample of 2,142 adults, found 17.8% living with obesity and 39.8% with overweight. Records of 440,590 adults who attended Dubai Academic Health Corporation facilities between 2018 and 2023 showed 28.0% with obesity. That second figure covers people who used public health services, so it is not a random sample of Dubai residents.
They are measuring different things. WHO reports a national age-standardized obesity estimate, while Dubai studies often report either overweight plus obesity or obesity alone in large local health-system samples. The question is not which source is real, but which source fits the use case.
IDF estimates that 1.274 million adults in the UAE were living with diabetes in 2024. Its age-standardized prevalence estimate is 20.7%, and it also estimates that 64.0% of diabetes cases were undiagnosed.
In March 2025, MoHAP said obesity is a strategic priority for the UAE health system. It highlighted work with WHO, obesity-indicator training, a national scientific guide for obesity management and weight control, and a National Health and Nutrition Survey, which was published on January 6, 2026 and reports adult obesity at 22.4%. On October 6, 2026, MoHAP said it had started implementing a resolution that caps sodium, sugar and fat in selected packaged foods, and the ministry linked the measure to reducing obesity and other noncommunicable diseases.
Grand View Research estimates the UAE GLP-1 receptor agonist market generated USD 257.2 million in 2025 and could reach USD 875.9 million by 2033, implying a 15.3% CAGR. That should be read as market intelligence, not official prescription-volume reporting.
No. No UAE registration of retatrutide as a medicine was found. Retatrutide is not approved anywhere; Eli Lilly says it is legally available only to participants in its clinical trials. Remy Research sells it for in-vitro laboratory research only, not for human or veterinary use.

Our Research Standards and Clinical Practice Recommendations

This article prioritizes peer-reviewed UAE prevalence data, WHO and IDF reference datasets, MoHAP policy updates, and clearly labeled market-intelligence estimates. We keep epidemiology, policy, and research-supply context separate to reduce confusion between public-health data and commercial interpretation. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews research articles covering GLP-1 receptor agonists, triple agonists, and the obesity drug pipeline. Its review checks sources, numerical claims, scientific and regulatory-status accuracy, and compliance wording.

About the editorial team →
References & Citations
  1. Abdelgadir E, Rashid F, Bashier A, et al. Prevalence of overweight and obesity in adults from the Middle East: A large-scale population-based study. Diabetes, Obesity and Metabolism. 2025;27(7):3676-3685. https://doi.org/10.1111/dom.16389
  2. World Health Organization. Age-standardized prevalence of obesity among adults (18+ years), Global Health Observatory indicator NCD_BMI_30A, United Arab Emirates (2024: 31.6%, UI 27.1–36.3%; May 2026 data release). Accessed October 20, 2026. data.who.int/indicators/i/C6262EC/BEFA58B
  3. International Diabetes Federation. United Arab Emirates country profile, IDF Diabetes Atlas 11th edition. diabetesatlas.org/data-by-location/country/united-arab-emirates/
  4. Ministry of Health and Prevention (UAE). Combating obesity is a strategic health priority, overseen by a highly skilled national team. 27 March 2025. mohap.gov.ae
  5. World Obesity Federation. Despite significant progress, obesity management remains a challenge in the UAE. 2024 UAE briefing and national summary. worldobesity.org
  6. Grand View Research. UAE GLP-1 Receptor Agonist Market Size & Outlook, 2026-2033. grandviewresearch.com
  7. Novo Nordisk juggles pipeline promise and pricing pressure as UAE hub opens new growth corridor. ad-hoc-news. May 2026. ad-hoc-news.de
  8. U.S. Food & Drug Administration. FDA approves first new molecular entity under national priority voucher program — Foundayo (orforglipron). April 1, 2026. fda.gov
  9. Gulf News. UAE approves Foundayo (orforglipron) — second country worldwide. April 3, 2026. gulfnews.com
  10. Eli Lilly. Lilly reports second-quarter 2026 financial results — Mounjaro WW $9.9B (+91%); Zepbound $4.9B (+44%); total revenue $23.0B (+48%). August 5, 2026. prnewswire.com
  11. Novo Nordisk. Q1 2026 Financial Results — DKK 96.8B (+32% CER); obesity care +22% CER; Wegovy pill DKK 2.26B. May 6, 2026. novonordisk.com
  12. Healthcare MEA / Aletihad. Beneath the Surface: The Hidden Socioeconomic Impacts of Weight Loss (Whiteshield, commissioned by Lilly with the UAE Ministry of Economy and Tourism): 1.2M+ adults out of obesity, +$51B GDP by 2031. May 2026. healthcaremea.com
  13. Gulf News / Healthcare MEA. Novo Nordisk announces UAE as global pharmaceutical distribution hub serving ~70 countries, 2.6M patients. May 22, 2026. gulfnews.com
  14. World Health Organization. Obesity and overweight (fact sheet, October 7, 2026): higher-than-optimal BMI caused an estimated 3.7 million deaths in 2023. who.int
  15. Ministry of Health and Prevention (UAE) / WHO. UAE National Health Survey 2017–2018 — adult obesity prevalence 27.8%. cdn.who.int
  16. Ministry of Health and Prevention (UAE). MoHAP publishes landmark National Health Survey — National Health and Nutrition Survey 2024–2025; 22.4% of adults living with obesity. January 6, 2026. mohap.gov.ae
  17. Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3); BLA submission planned Q1 2027. July 23, 2026. investor.lilly.com
  18. Reuters. Novo Nordisk wins EU approval for Wegovy weight-loss pill (pill available in the US, UK and UAE). July 15, 2026. reuters.com
  19. Department of Health – Abu Dhabi. Abu Dhabi expands access to innovative daily oral obesity treatment (Personalised Weight Management Programme with ADPHC; initial rollout at ICLDC). April 24, 2026. doh.gov.ae
  20. Quartz via Yahoo Finance. Novo Nordisk launches Wegovy pill in UAE, its first global market (first country outside the U.S.). June 3, 2026. finance.yahoo.com
  21. Reuters. Novo Nordisk launches Wegovy weight-loss pill in Germany (first EU launch market). September 1, 2026. reuters.com
  22. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published online September 29, 2026. doi:10.1056/NEJMoa2604169
  23. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). Lancet. 2026;408(10563):1455–1472 (online September 29, 2026). doi:10.1016/S0140-6736(26)01861-1
  24. Eli Lilly and Company. Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 (retatrutide is legally available only to participants in Lilly’s clinical trials). September 15, 2026. prnewswire.com
  25. Fatima S, et al. Prevalence of Overweight and Obesity and Their Associations With Screen Time and Other Behavioral Factors Among Adolescents in the United Arab Emirates. Cureus. Published October 11, 2026 (688 adolescents aged 14–18; not nationally representative). doi:10.7759/cureus.117775
  26. AlMuhairi S, et al. Metabolic syndrome among adults aged 18–40 years in the United Arab Emirates: prevalence and associated factors using harmonized criteria (UAE Healthy Future Study). Front Public Health. 2026;14:1868692 (published September 23, 2026). PMID 42846497. doi:10.3389/fpubh.2026.1868692
  27. Aletihad / WAM (Emirates News Agency). MoHAP starts implementing resolution setting caps on levels of sodium, sugar, fats in selected food products. October 6, 2026. aletihad.ae
  28. World Health Organization. WHO issues first global guidelines on child and adolescent obesity. October 7, 2026. who.int
  29. European Medicines Agency. New oral GLP-1 medicine for weight management and type 2 diabetes (CHMP positive opinion on Foundayo, orforglipron, adopted October 15, 2026; European Commission decision pending). October 16, 2026. ema.europa.eu
  30. Mamdouh H, Hussain HY, Ibrahim GM, et al. Prevalence and associated risk factors of overweight and obesity among adult population in Dubai: a population-based cross-sectional survey in Dubai, the United Arab Emirates (Dubai Household Health Survey 2019; 2,142 adults, weighted). BMJ Open. 2023;13(1):e062053. PMID 36693685. doi:10.1136/bmjopen-2022-062053

For the seasonal evidence, see GLP-1 and Ramadan in the UAE: Gulf fasting studies and evidence gaps.